Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exjade for Iron Overload in Sickle Cell Disease
NCT00981370Phase 3Terminated
- Sponsor
- Children's Hospital Los Angeles
- Start
- Apr 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in transfusional hemosiderosis, sponsored by Children's Hospital Los Angeles. Primary endpoint: Red Cell Survival as Assessed by Hemoglobin Level, Reticulocyte Count, Lactic Acid Dehydrogenase, and Plasma Hemoglobin at 12 months. Started Apr 2009; status: terminated.
02
Drugs
deferasirox
03
Conditions
transfusional hemosiderosis
Beyond the preview
Go deeper on NCT00981370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981370.